Timothy Walbert
Timothy Walbert is a Senior Advisor to Patient Square Capital. Mr. Walbert currently serves as Managing Partner of HRZN Partners LLC and a Senior Advisor to Amgen. Most recently, he was Chairman, President, and Chief Executive Officer of Horizon Therapeutics, which he grew to approximately $4 billion in annual sales prior to its $28.3 billion acquisition by Amgen in 2023; earlier, he led IDM Pharma Inc. through its acquisition by Takeda and held senior roles at Abbott (now AbbVie), where he led the global launch of HUMIRA®, as well as at G.D. Searle & Company, Merck & Co., and Wyeth.
Mr. Walbert currently serves on the boards of several public and private companies, including Mirum Pharmaceuticals, Sagimet Biosciences, BioMarin Pharmaceutical, Odyssey Therapeutics, Cour Pharmaceuticals, Catalent, Crystalys Therapeutics, and Latigo Biotherapeutics, where he serves as Chairman. His prior board experience includes Aurinia Pharmaceuticals, Exicure (Chairman), Assertio (Chairman), Raptor Pharmaceutical Corp., Century Therapeutics, XOMA Corporation, and Sucampo Pharmaceuticals.
Mr. Walbert holds a B.A. from Muhlenberg College.